Advancement to Phase 3 is a major milestone for SAB’s unique DiversitAb immunotherapy platform that produces fully human polyclonal antibodies without human donors
It is a recombinant nanoparticle protein-based vaccine
Seed Spark is an online entrepreneurship program offered by Stanford Seed. Health Sensei emerged as a winner competing with 86 startups from their May-Aug 2021 graduating cohort
Emergency Use Authorisation (EUA) is granted for individuals 65 years of age and older, and individuals ages 18 through 64 within certain high-risk groups
Industry leaders to increase patient access to clinical research and scale remote enrollment of participants for trial sponsors to promote increased health equity
Surufatinib is the third potential new medicine discovered by the company to enter into clinical development in Japan
In participants 5 to 11 years of age, the vaccine was safe, well-tolerated and showed robust neutralising antibody responses. Results in children under 5 years of age are expected as soon as later this year
Clindamycin Phosphate Foam, 1% is the generic version of Evoclin Foam, 1%
The CASPIAN Phase III trial in extensive-stage small-cell lung cancer is the longest survival follow-up ever reported for immunotherapy treatment in this setting
In the final analysis of Phase 3 COVE study data, SPIKEVAX showed 93% efficacy, with the efficacy remaining durable through six months after the administration of the second dose
Subscribe To Our Newsletter & Stay Updated
